Sunshine will market and sell this new pharmaceutical product under its own label.
Sunshine is currently in the process of securing a Drug Identification Number ("DIN") for its own label of Anastrozole from Health Canada. The Company is also working on obtaining a Drug Establishment License ("DEL") from Health Canada.
Upon receipt of the DIN, Sunshine will be able to accept orders for its SBI-Anastrozole. Sunshine expects to build a portfolio of "SBI" label Generic Pharmaceuticals over time.
Revenues from the sales of Generic Products are intended to be used to finance the Company’s proprietary drug development program including Adva-27a, the Company’s flagship anticancer compound.
A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.